Eledon Pharmaceuticals (ELDN) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Eledon Pharmaceuticals (ELDN) over the past year, gaining 0.8% versus a loss of 38.1%. Over five years, ELDN leads with a -58.1% price change compared with -97.0% for SABS. SAB Biotherapeutics is the larger company by market cap ($230.2 million vs $173.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | SABS |
|---|---|---|
| Share price | $2.13 | $2.53 |
| Market cap | $173.09M | $230.20M |
| 1-day change | -6.17% | -2.32% |
| YTD return | +41.06% | -32.35% |
| 1-year return | -38.08% | +0.80% |
| 5-year return | -58.07% | -97.00% |
| EPS (TTM) | $-0.90 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-45.62M | $13.27M |
| 52-week high | $4.60 | $5.15 |
| 52-week low | $1.35 | $2.45 |
| Distance from 52-week high | -53.70% | -50.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +322.54% | +360.08% |
| Average volume | 914.37K | 527.29K |
| Shares outstanding | 81.26M | 90.99M |
| Employees | 33 | 86 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed ELDN by 38.9 percentage points over the past year.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Healthcare · Biotechnology · 33 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
ELDN vs SABS FAQ
Which is bigger, Eledon Pharmaceuticals or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $230.20M compared with $173.09M for Eledon Pharmaceuticals (ELDN).
Which stock has performed better over the past year, ELDN or SABS?
SABS returned +0.80% over the past 12 months, compared with -38.08% for ELDN (price return, excluding dividends). Past performance does not predict future results.
Are Eledon Pharmaceuticals and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.